NTX 010
Alternative Names: NTX-010; Seneca Valley Virus-001; SVV-001Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Novartis
- Developer Alliance for Clinical Trials in Oncology; National Cancer Institute (USA); Neotropix; North Central Cancer Treatment Group
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuroendocrine tumours; Small cell lung cancer
Most Recent Events
- 28 Mar 2017 NCI terminates a phase II trial as interim analysis declared futility in Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT01017601)
- 31 May 2013 Safety and efficacy data from a phase II trial in Small cell lung cancer presented at the 49th Annual Meeting of the American Society of Clinical Oncology
- 23 Feb 2010 Neotropix completes enrolment in its Phase-I trial (NCT00314925) for Neuroendocrine tumours in USA